Guildford, UK, 21 May 2012:  ReNeuron announces that its Chief Executive Officer, Michael Hunt, will present to delegates today at the World Stem Cells & Regenerative Medicine Conference in London.

Mr Hunt will provide a summary of the Company’s stem cell technologies and its ReN001 stem cell therapy targeting stroke disability. The Company will provide a further update on interim data from the PISCES Phase I clinical trial with ReN001 in June.

Further details of the Congress may be found at

Separately, ReNeuron notes last week’s announcement from Osiris Therapeutics Inc., that its stem cell treatment for graft versus host disease, Prochymal, has gained marketing approval in Canada, marking the world’s first marketing authorisation for a manufactured stem cell drug.

This marketing authorisation represents a significant milestone in the field and is a positive development for ReNeuron and other stem cell companies developing similar “off-the-shelf” stem cell treatments targeting other major unmet medical needs.

Michael Hunt, Chief Executive Officer of ReNeuron, said:

“We congratulate Osiris on the achievement of the world’s first marketing approval for an off-the-shelf stem cell drug. We believe that this is a defining moment, opening up the therapeutic paradigm of stem cell treatments of this kind.  Our own stem cell treatments are also off-the-shelf in nature, so it is particularly reassuring to see that this completely new approach to medicine is being increasingly endorsed by regulatory authorities around the globe.”


ReNeuron        +44 (0) 1483 302560
Michael Hunt, Chief Executive Officer
Pat Huggins, Head of Finance 

  1. Buchanan                             +44 (0) 20 7466 5000
    Mark Court, Sophie Cowles                 
    Cenkos Securities      +44 (0) 20 7397 8900
    Stephen Keys, Adrian Hargrave (NOMAD and Broker)
    Andy Roberts (Sales)

About ReNeuron
ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron’s lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research.  The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as “should”, “expects”, “estimates”, “believes” or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron’s current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron’s actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.